Page last updated: 2024-11-08

afimoxifene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5352135
CHEMBL ID279301
CHEBI ID92076
SCHEMBL ID2132301
SCHEMBL ID640496
MeSH IDM0066724
PubMed CID449459
CHEMBL ID489
CHEBI ID44616
SCHEMBL ID9189
MeSH IDM0066724
PubMed CID5284643
CHEMBL ID10041
SCHEMBL ID2165503
MeSH IDM0066724

Synonyms (163)

Synonym
LS-15148
dtxsid3037094 ,
CHEMBL279301 ,
e-4-hydroxytamoxifen
cas-68392-35-8
NCGC00257332-01
tox21_303657
dtxcid0028161
SCHEMBL2132301
BCP9000165
BCP9000243
BCP0726000017
BCP0726000194
cis-4-hydroxytamoxifen
unii-ake3ph0iml
ake3ph0iml ,
4-((1e)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
afimoxifene, e-isomer
AKOS015894466
(e)-4-hydroxytamoxifen
174592-47-3
SCHEMBL640496
DTXSID10169854
CHEBI:92076
J-011016
cis-4-hydroxy tamoxifen discontinued
tamoxifen, 4-hydroxy-, (z)- - cas 68047-06-3
CP-0071
(e)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
HY-16950B
CS-0065038
Q27273974
4-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
cis-4-hydroxy tamoxifendiscontinued
bdbm50551582
(e)-afimoxifene
E84529
BIDD:PXR0104
BIDD:ER0193
MLS001077346
BRD-K04210847-001-01-1
smr000058939
tamoxifen, 4-hydroxy-, (z)-
MLS000069742 ,
HSCI1_000353
phenol, 4-((1z)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-
trans-4-hydroxytamoxifen
brn 4910749
4-((1z)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol
ici 79,280
phenol, 4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-, (z)-
trans-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol
tamogel (tn)
D06551
afimoxifene (usan/inn)
68392-35-8
bdbm20608
[3h]4-oht
afimoxifene
4-[(1z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol
cid_449459
chembl489 ,
hydroxytamoxifen
68047-06-3
4-hydroxytamoxifen
C05011
(z)-4-hydroxytamoxifen, >=98% z isomer
2BJ4
(z)-4-hydroxytamoxifen
4-oh-tam
NCGC00164399-01
phenol, 4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)-,
c26h29no2
4-monohydroxytamoxifen
tamogel
ici 79280
chebi:44616 ,
SR-01000759243-5
sr-01000759243
NCGC00164399-02
dtxcid802384
cas-68047-06-3
tox21_200943
NCGC00258497-01
dtxsid7022384 ,
4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenol
HMS2231F20
AKOS016010361
17197f0kym ,
afimoxifene [usan:inn]
ccris 8580
unii-17197f0kym
95k54647bz ,
unii-95k54647bz
(z)-4-oht
(e/z)-4-hydroxytamoxifen
(z)-4-hydroxy tamoxifen
S8956
DB04468
SCHEMBL9189
afimoxifene, z-isomer
ici-79280
mfcd00278780
65213-48-1
4-[(1z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]phenol
(z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
OPERA_ID_600
4-(1-[4-(dimethylaminoethoxy)phenyl]-2-phenyl-1-butenyl)phenol
(z)-4-(1-(4-(2-(dimethylamino)ethoxy)-phenyl)-2-phenylbut-1-en-1-yl)phenol
mfcd00468090
4-{(1z)-1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenol
SR-01000759243-3
4-[(1z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenyl-1-buten-1-yl]phenol
(z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
TXUZVZSFRXZGTL-QPLCGJKRSA-N
z-4-hydroxytamoxifen
4-hydroxy tamoxifen
4-oh tamoxifen
1077-29-8
Q4689254
HB2508
4-hydroxytamoxifen (e) and (z) isomers (50:50)
4-hydroxytamoxifen ≥70% z isomer (remainder primarily e-isomer)
(z)-4-hydroxytamoxifen (z-4-oht)
HB6040
HB6095
EX-A4661
HY-16950A
CS-0003592
A904472
4-[(1z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
MS-26417
4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
r-lipoic acid potassium compund
GLXC-26379
4-[(z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-1-phenylbut-1-en-2-yl] phenol
4ht ,
gtpl2817
NCGC00091028-01 ,
4-hydroxy-tamoxifen
4'-hydroxytamoxifen
4-{(1z)-1-[{4-[2-(dimethylamino)ethoxy]phenyl}(phenyl)methylene]propyl}phenol
4-ht
trans-hydroxytamoxifen
CHEMBL10041 ,
4'-hydroxy tamoxifen (contains up to 10% e isomer)
NCGC00091028-02
82413-23-8
SCHEMBL2165503
AKOS030532715
4??-hydroxy tamoxifen
DTXSID00873019
bdbm50180684
4 inverted exclamation mark -hydroxy tamoxifen (contains up to 10% e isomer)
Q27073761
(z)-4'-hydroxytamoxifen
4hydroxy tamoxifen
4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol
4 inverted exclamation mark -hydroxy tamoxifen
4'-hydroxy tamoxifen (contains up to 10per cent e isomer)
HY-124414
CS-0086430

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Results of the analysis showed that women who experienced at least one TAM-related side effect had significantly higher levels of TAM than women not experiencing any TAM-related side effects."( Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
Danton, M; Flaws, JA; Gallicchio, L; Lewis, LM; Lim, CK; Lord, G; Tkaczuk, K, 2004
)
0.32
"Acitretin is a synthetic retinoid used for severe extensive psoriasis and it has been shown to be an effective and a safe therapeutic drug for other diseases including cancer when used in combination with other agents."( Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity.
Custódio, JB; Ribeiro, MP; Rocha-Pereira, P; Santos, MS; Santos-Silva, A; Silva, FS, 2013
)
0.39
" However, tamoxifen produces adverse effects that could be due to its ability to induce cellular DNA damage."( Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells.
Ismail, NF; Yaacob, NS, 2014
)
0.4
"The findings indicate that TH could afford protection of non-cancerous cells from the toxic effects of tamoxifen by increasing the efficiency of DNA repair mechanism in these cells."( Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells.
Ismail, NF; Yaacob, NS, 2014
)
0.4
" A preliminary assessment of their acute aquatic toxicity at two trophic levels by means of quantitative structure-activity relationship models showed that the identified byproducts were up to 110-fold more toxic than the parent compounds."( Transformation of tamoxifen and its major metabolites during water chlorination: Identification and in silico toxicity assessment of their disinfection byproducts.
Barceló, D; López de Alda, M; Negreira, N; Regueiro, J, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" The presence of kaempferol did not alter the pharmacokinetic parameters of a metabolite of tamoxifen, 4-hydroxytamoxifen."( Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
Choi, JS; Piao, Y; Shin, SC, 2008
)
0.35
" Pharmacokinetic parameters of tamoxifen and 4-hydroxytamoxifen were determined in rats after oral (10 mg/kg) and intravenous (2 mg/kg) administration of tamoxifen in the presence and absence of myricetin (0."( Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Choi, JS; Kim, J; Li, C; Lim, SC, 2011
)
0.37
" Pharmacokinetic parameters of tamoxifen and 4-hydroxytamoxifen were determined in rats after an oral administration of tamoxifen (10 mg/kg) to rats in the presence and absence of baicalein (0."( Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
Choi, H; Choi, J; Kim, M; Li, C, 2011
)
0.37
" Period 1, day 1, subjects were administered tamoxifen 40 mg followed by 23 days of blood sampling for pharmacokinetic analyses."( Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
Braley, G; Liang, Y; Lubaczewski, S; Matschke, K; Nichols, AI; Ramey, T, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" We therefore investigated the efficacy of the farnesyltransferase inhibitor (FTI) R115777 (tipifarnib) in combination with tamoxifen in MCF-7 human breast cancer models both in vitro and in vivo."( The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Detre, S; Dowsett, M; Head, JE; Howes, A; Johnston, SR; Kaye, S; Martin, LA; Pancholi, S; Quinn, E; Salter, J, 2007
)
0.34
" During period 2, subjects received desvenlafaxine 100 mg/d for 28 days; a single dose of tamoxifen 40 mg was administered with desvenlafaxine 100 mg on day 7, followed by 23 days of blood sampling."( Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
Braley, G; Liang, Y; Lubaczewski, S; Matschke, K; Nichols, AI; Ramey, T, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" The present data suggest that estrogen sulfates can play an important biological role in the target tissues of the fetus, and that the enzymatic mechanisms of the bioavailability of E2 for the biological responses of the hormone can be operated in the target tissue itself."( Transformation of estrone, estradiol, and estrone sulfate in uterine and vaginal isolated cells of fetal guinea pig. Effect of various antiestrogens in the conversion of estrone sulfate to estradiol.
Chetrite, G; Pasqualini, JR; Urabe, M, 1993
)
0.29
" It is assumed that the enhanced and accelerated uptake of liposomal HT in the cell line with relative drug resistance can increase the intracellular bioavailability of HT."( Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro.
Behrens, D; Fichtner, I; Teppke, AD; Zeisig, R, 2004
)
0.32
" This study investigated the effect of quercetin, a dual inhibitor of CYP3A4 and P-gp, on the bioavailability and pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, in rats."( Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
Choi, JS; Li, X; Shin, SC, 2006
)
0.33
" The enhanced bioavailability of oral tamoxifen by oral kaempferol could have been due to an inhibition of CYP3A and P-gp by kaempferol."( Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
Choi, JS; Piao, Y; Shin, SC, 2008
)
0.35
"This study examined the effect of morin on the bioavailability and pharmacokinetics of tamoxifen and its metabolite, 4-hydroxytamoxifen, in rats."( Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Choi, JS; Piao, YJ; Shin, SC,
)
0.13
"The aim of this study was to investigate the effect of naringin on the bioavailability and pharmacokinetics of tamoxifen and of its metabolite, 4-hydroxytamoxifen in rats."( Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin.
Choi, JS; Kang, KW, 2008
)
0.35
"The effects of epigallocatechin gallate (EGCG) on the oral bioavailability and pharmacokinetics of tamoxifen and its metabolite, 4-hydroxytamoxifen, were investigated in rats."( Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Choi, JS; Shin, SC, 2009
)
0.35
" Consequently, the absolute bioavailability (AB) of tamoxifen in the presence of silybinin (2."( Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Choi, JS; Choi, SJ; Kim, CS; Li, C; Park, CY, 2010
)
0.36
"This study examined the effect of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its metabolite, 4-hydroxytamoxifen, in rats."( Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Choi, JS; Kim, J; Li, C; Lim, SC, 2011
)
0.37
" As BCA is an inhibitor of CYP 3A and P-gp it was expected to increase the bioavailability of tamoxifen, a known substrate of CYP3A4/Pgp."( Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats.
Ali, MM; Jain, GK; Kohli, K; Raju, KS; Singh, SP, 2012
)
0.38
" Consequently, the absolute bioavailability of tamoxifen in the presence of baicalein (3 and 10 mg/kg) was significantly increased by 47."( Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
Choi, H; Choi, J; Kim, M; Li, C, 2011
)
0.37
"The effects of curcumin, a natural anti-cancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its metabolite, 4-hydroxytamoxifen, were investigated in rats."( Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
Cho, YA; Choi, JS; Lee, W, 2012
)
0.38
" Pharmacokinetic studies were conducted to evaluate the metabolism and bioavailability of the drug in mice."( Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
Miele, L; Wang, G; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q, 2015
)
0.42
" The boronic prodrug was shown to have far superior bioavailability of 4-OHT compared to tamoxifen or 4-OHT administration as measured by the area under the plasma concentration time curve (AUC), plasma peak concentrations, and drug accumulation in tumor tissues."( Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
Miele, L; Wang, G; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q, 2015
)
0.42
" We describe the design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs."( Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Abrams, T; Baird, J; Burks, HE; Firestone, B; Gaither, LA; Hamann, LG; He, G; Kim, S; Kirby, CA; Lombardo, F; Macchi, KJ; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Springer, C; Sun, Y; Thomsen, NM; Tiong-Yip, CL; Tria, GS; Wang, C; Wang, J; Yu, B, 2018
)
0.48
" However, the solely clinically used SERD fulvestrant, is low orally bioavailable and requires intravenous injection, which severely limits its clinical application."( Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Hu, Z; Huang, J; Li, C; Ning, W; Tang, C; Xin, L; Zhao, C; Zhou, HB, 2021
)
0.62
" The other therapies like hormonal therapy, surgery, radiotherapy, and immune therapy are in use but showed many side effects like bioavailability issues, non-selectivity, pharmacokinetic-pharmacodynamic problems."( Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Arya, GC; Jaitak, V; Kaur, K, 2021
)
0.62
" Furthermore, It has superior oral bioavailability (AUC = 2547."( Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
Akerstrom, VL; Bratton, MR; Guo, S; Liu, J; Ma, P; Ma, Y; Miele, L; Pannuti, A; Skripnikova, EV; Wang, G; Wiese, TE; Yuan, C; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves of GCDFP-15 mRNA contents and GCDFP-15 levels in culture media and cells versus hormone or antihormone concentration have been established."( Stimulatory effect of oestradiol-17 beta and tamoxifen on gross cystic disease fluid protein 15,000 production and mRNA levels in T47D human breast cancer cells.
Carlisi, I; Collette, J; Dejardin, L; Delvenne, C; Franchimont, P; Gol-Winkler, R; Haagensen, DE, 1991
)
0.28
" By contrast, the timing of the ODC activity peak induced by tamoxifen and monohydroxytamoxifen was highly dependent upon the dosing conditions and was delayed to 18 h at lower tamoxifen doses."( Estrogen- and antiestrogen-induced ornithine decarboxylase activity and uterine growth in the rat.
Branham, WS; Leamons, ML; Sheehan, DM, 1988
)
0.27
" This became more clearly apparent when cells were treated with the 4-hydroxylated derivatives of these compounds where, because of enhanced affinity for the oestrogen receptor (ER), the dose-response curves for the two components could be separated."( Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells.
Hall, RE; Ruenitz, PC; Sutherland, RL; Watts, CK, 1987
)
0.27
" The partial uterotrophic effect of monohydroxytamoxifen and full uterotrophic effects of estradiol were both inhibited by high doses of LY117018 at an approximate dosage ratio of 1:24, w/w."( Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
Gosden, B; Jordan, VC, 1983
)
0.27
" Dose-response analysis showed that, in the R27 variant, TAM and OH-TAM acquired the ability to induce the Mr 52,000 protein at concentrations compatible with their relative affinities for the estrogen receptor, while these antiestrogens were inefficient in the wild MCF7 cells."( Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Derocq, D; Lippman, ME; Nawata, H; Rochefort, H; Vignon, F, 1984
)
0.27
" However, in the rat, LY117018 was more effective against the less potent compound tamoxifen, at a 6:1 dosage ratio compared with a 24:1 dosage ratio required for the potent compound monohydroxytamoxifen."( Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Gosden, B; Jordan, VC, 1983
)
0.27
" Interestingly, a dose-response study showed that Cre-ER(T2) was approximately 10-fold more sensitive to OHT induction than Cre-ER(T)."( Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases.
Bornert, JM; Brocard, J; Chambon, P; Indra, AK; Metzger, D; Warot, X; Xiao, JH, 1999
)
0.3
" Dose-response experiments indicated that the lowest stimulatory concentration of 17 beta-estradiol, DHT, and norgestrel is 10(-11) M, 10(-10) M, and 10(-10) M, respectively."( The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474.
Diamandis, EP; Grass, L; Luo, LY,
)
0.13
" Tamoxifen forms liver DNA adducts in both short- and long-term dosing of rodents, and DNA adducts have also been reported in tissues of women undergoing tamoxifen therapy."( DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alpha-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells.
Brown, K; Farmer, PB; Gaskell, M; Martin, EA; McLuckie, KI; Roberts, GC; Routledge, MN, 2002
)
0.31
" Ovary weight, uterus weight, peak plasma GH concentration, and hepatic CYP2A1 content were decreased 37 days after treatment with tamoxifen at a dosage of 20 mg/kg, but expression of other P450 enzymes was not affected."( Persistent suppression of hepatic CYP2A1 expression and serum triiodothyronine levels by tamoxifen in intact female rats: dose-response analysis and comparison with 4-hydroxytamoxifen, fulvestrant (ICI 182,780), and 17beta-estradiol-3-benzoate.
Bandiera, SM; Ickenstein, LM, 2002
)
0.31
" After oral dosing in mice, tam and the potent metabolite 4-hydroxytamoxifen (4-hydroxytam), were detectable in liver and lung tissue, but not in serum."( Tamoxifen administration and metabolism in nude mice and nude rats.
Gjerde, J; Kisanga, ER; Lien, EA; Mellgren, G; Schjøtt, J, 2003
)
0.32
" We investigated concentrations of tamoxifen, 4-hydroxytamoxifen, N-desmethyltamoxifen, and N-didesmethyltamoxifen in serum, normal breast, and breast cancer tissues during conventional dosage and two low-dose regimens."( Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Decensi, A; Gjerde, J; Guerrieri-Gonzaga, A; Kisanga, ER; Lien, EA; Pelosi, G; Pesci-Feltri, A; Pigatto, F; Robertson, C; Serrano, D, 2004
)
0.32
" DES alone affected mammary growth (an inverted-U-shaped dose-response curve) both in male and female mice."( Mouse bioassay to assess oestrogenic and anti-oestrogenic compounds: hydroxytamoxifen, diethylstilbestrol and genistein.
Köhlerová, E; Skarda, J, 2004
)
0.32
"Consistent with previous reports, the dose-response of the E2 effect on the PR expression indicated an ED(50) value of approximately 60 pM and the maximum induction of PR mRNA was nearly ten-fold."( Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Desta, Z; Flockhart, DA; Lim, YC; Skaar, TC, 2005
)
0.33
" Dose-response curves of different ligands could be obtained for each receptor interaction."( Diffusion-time distribution analysis reveals characteristic ligand-dependent interaction patterns of nuclear receptors in living cells.
Izewska, P; Jankevics, H; Leufgen, K; Pick, H; Prummer, M; Vogel, H, 2005
)
0.33
" If the results are further confirmed in the clinical trials, the tamoxifen dosage should be adjusted when tamoxifen is administered with quercetin or quercetin-containing dietary supplements in order to avoid potential drug interactions."( Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
Choi, JS; Li, X; Shin, SC, 2006
)
0.33
" Interestingly, licoflavone C exhibited a dose-dependent antagonistic activity at concentrations up to 10(-4) M, but stimulated beta-galactosidase expression at higher concentrations resulting in a U-shaped-like dose-response curve."( Estradiol-antagonistic activity of phenolic compounds from leguminous plants.
Bertoli, A; Garritano, S; Noccioli, C; Pinto, B; Pistelli, L; Reali, D, 2008
)
0.35
" The increased bioavailability of tamoxifen in the presence of morin should be taken into consideration for dosage regimens due to potential drug interaction."( Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Choi, JS; Piao, YJ; Shin, SC,
)
0.13
" If these results are confirmed in clinical trials, the tamoxifen dosage should be adjusted when tamoxifen is administered with silybinin or silybinin-containing dietary supplements."( Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
Choi, JS; Choi, SJ; Kim, CS; Li, C; Park, CY, 2010
)
0.36
" The plasma concentrations of TOR and its N-desmethyl (NDM) and 4-hydroxy (4-OH) metabolites during steady-state dosing with TOR were also determined."( Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
Barrett, CM; Bohl, CE; Coss, CC; Dalton, JT; He, Y; Kim, J; Li, CM; Mohler, ML; Veverka, KA, 2013
)
0.39
" The estrogenic potencies of the dyes and wastewater samples were evaluated by dose-response curves and compared to the dose-response curve of 17β-estradiol (E2), the reference compound."( Estrogenic and anti-estrogenic activity of 23 commercial textile dyes.
Bartegi, A; Bazin, I; De Waard, M; Gonzalez, C; Haj Hamouda, Y; Ibn Hadj Hassine, A; Lopez-Ferber, M; Mnif, W, 2012
)
0.38
" Our results suggest that intermittent dosing regimes of drugs that restore wild-type tumor-suppressor function onto mutant, inactive p53 proteins will prove to be more efficacious than traditional chronic dosing by similarly reducing adaptive resistance."( Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy.
Berger, MS; Evan, GI; Hanahan, D; Li, N; Lyubynska, N; Persson, AI; Rostker, F; Shchors, K; Swigart, LB; Tihan, T; Weiss, WA, 2013
)
0.39
"With increasing dosage of quercetin, significant decrease in proliferation and increase in apoptosis was observed."( Quercetin reverses tamoxifen resistance in breast cancer cells.
Chen, T; Feng, D; Kong, H; Lin, Q; Qi, K; Tao, L; Wang, H; Wei, W; Zhang, H,
)
0.13
"Proliferation inhibition and apoptosis in MCF-7Ca/TAM-R cells increase with increasing dosage of quercetin."( Quercetin reverses tamoxifen resistance in breast cancer cells.
Chen, T; Feng, D; Kong, H; Lin, Q; Qi, K; Tao, L; Wang, H; Wei, W; Zhang, H,
)
0.13
" Further, ZB497 was more effective than tamoxifen at lowered dosage in inhibiting the growth of xenograft tumors in mice."( Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
Miele, L; Wang, G; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q, 2015
)
0.42
" The drug is usually dosed 20 mg/d irrespective of interindividual variation in drug clearance."( Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi, AK; Hatschek, T; Karim, H; Lafolie, P; Östervall, J; Pohanka, A; Vitols, S, 2016
)
0.43
"Large interindividual variation of tamoxifen and endoxifen with stable intraindividual levels, and too low levels of endoxifen in a considerable proportion of patients strongly support that therapeutic drug monitoring and individualized dosing could lead to optimal exposure and hopefully better outcome."( Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi, AK; Hatschek, T; Karim, H; Lafolie, P; Östervall, J; Pohanka, A; Vitols, S, 2016
)
0.43
" These results suggest that fucoidan in the studied form and dosage could be taken concomitantly with letrozole and tamoxifen without the risk of clinically significant interactions."( The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Fitton, JH; Lowenthal, RM; McGuinness, G; Olesen, I; Oliver, LJ; Patel, R; Peterson, GM; Shastri, M; Tocaciu, S, 2018
)
0.48
" Importantly, the result indicated that the low dosage does not induce significant systemic recombination in remote skeletal tissues."( Activation of creER recombinase in the mouse calvaria induces local recombination without effects on distant skeletal segments.
Hou, J; Intini, G; Lin, CP, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
estrogen receptor antagonistAn antagonist at the estrogen receptor.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Tamoxifen metabolism013
Tamoxifen Action Pathway1027
Tamoxifen Metabolism Pathway1027
4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression011

Protein Targets (100)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency41.28630.002541.796015,848.9004AID1347395; AID1347397; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency36.24863.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.28680.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency32.30660.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency32.30660.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency15.97140.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency33.30590.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency40.32130.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency45.24120.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency39.03800.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency35.34110.000417.946075.1148AID1346784; AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.18020.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.85570.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency34.16720.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency5.69550.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.03270.000229.305416,493.5996AID1259244; AID1259248
caspase-3Homo sapiens (human)Potency40.32130.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency32.24090.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency32.77830.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency36.248619.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency29.74460.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency71.80620.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency35.93640.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency35.93640.006723.496068.5896AID1346980
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.02270.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.02270.001551.739315,848.9004AID1259244
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.48130.044717.8581100.0000AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
acetylcholinesteraseHomo sapiens (human)Potency54.93780.002541.796015,848.9004AID1347395; AID1347397; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency7.94330.01846.806014.1254AID624417
pregnane X receptorRattus norvegicus (Norway rat)Potency31.62280.025127.9203501.1870AID651751
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency55.45553.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency45.39880.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency65.58310.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency65.58310.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency21.83690.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency12.62150.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency44.29170.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency35.48130.707912.194339.8107AID720542
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency34.44550.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency78.11950.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency62.89110.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency56.50050.000417.946075.1148AID1346784; AID1346795; AID1347036
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency40.32030.000214.376460.0339AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency58.70140.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.99290.000817.505159.3239AID1159527; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency54.97320.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency53.68820.375827.485161.6524AID588526; AID588527; AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency7.40800.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.32740.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720580
glucocerebrosidaseHomo sapiens (human)Potency19.95260.01268.156944.6684AID2101
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency44.66840.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency40.10030.001024.504861.6448AID588534; AID588535; AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency57.06520.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency55.67360.023723.228263.5986AID588541; AID743223; AID743241
caspase-3Homo sapiens (human)Potency34.44550.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency16.36010.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.02170.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency50.98820.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency61.81200.143427.612159.8106AID1159516; AID1159519
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency38.04040.154917.870243.6557AID1346877
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency55.090019.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency25.64580.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency50.60950.039147.5451146.8240AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency30.69960.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency17.55950.010039.53711,122.0200AID588545; AID588547
caspase-3Cricetulus griseus (Chinese hamster)Potency30.69960.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.11740.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency41.35020.042027.378961.6448AID743210; AID743228
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency28.18384.466824.832944.6684AID651749
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency23.95080.000627.21521,122.0200AID651741; AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency25.66510.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency7.62230.004611.374133.4983AID624296; AID624297
lamin isoform A-delta10Homo sapiens (human)Potency31.62280.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.01220.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency44.77190.002319.595674.0614AID651631; AID651743; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.01220.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency77.11390.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency77.11390.011912.222168.7989AID651632
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency79.43280.00137.762544.6684AID2120
retinoid X nuclear receptor alphaHomo sapiens (human)Potency39.81070.000817.505159.3239AID588546
farnesoid X nuclear receptorHomo sapiens (human)Potency44.66840.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency11.22020.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.57360.000229.305416,493.5996AID588513; AID588514
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency39.81070.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588537
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency44.66840.023723.228263.5986AID588541
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency44.66840.010039.53711,122.0200AID588545
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency22.38720.01789.637444.6684AID588834
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency50.11874.466824.832944.6684AID651749
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency39.87060.000627.21521,122.0200AID651741; AID720636
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency23.75300.00798.23321,122.0200AID2546; AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Cellular tumor antigen p53Homo sapiens (human)Potency44.66840.002319.595674.0614AID651743
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency33.49150.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.00230.00000.723732.7000AID1690956; AID1690969
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.00130.00010.529432.7000AID1690957; AID1690970
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)IC50 (µMol)20.00000.873010.721978.4000AID493155
Phospholipase D2Homo sapiens (human)IC50 (µMol)13.25000.00611.159810.0000AID1801138
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.01050.00000.723732.7000AID1263142; AID1263143; AID1337045; AID1469717; AID1469729; AID1506598; AID1594506; AID1594508; AID1768138; AID1797989; AID1798194; AID1829663; AID1829675; AID1830575
AromataseHomo sapiens (human)IC50 (µMol)530.00000.00001.290410.0000AID1307756
Estrogen-related receptor gammaHomo sapiens (human)IC50 (µMol)0.00840.00200.22732.0000AID1798194; AID1799022
Phospholipase D1Homo sapiens (human)IC50 (µMol)13.25000.00101.06568.5000AID1801138
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.01020.00010.529432.7000AID1797989; AID1829664; AID1829676
Lysine-specific histone demethylase 1AHomo sapiens (human)IC50 (µMol)50.00000.00312.16029.6000AID1737495
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.05060.00000.723732.7000AID1865885; AID1865893
Progesterone receptorHomo sapiens (human)IC50 (µMol)0.10000.00000.580710.0000AID1865894
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)0.00360.00010.529432.7000AID1865886
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen-related receptor gammaHomo sapiens (human)EC50 (µMol)0.01500.01500.66491.8990AID1798195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)DC500.00010.00010.03040.0910AID1768139
Estrogen receptorHomo sapiens (human)Ka0.00030.00020.00020.0003AID1865885
Estrogen receptor betaHomo sapiens (human)Ka0.00200.00200.02160.0412AID1865886
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (247)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
phosphatidic acid biosynthetic processPhospholipase D2Homo sapiens (human)
cytoskeleton organizationPhospholipase D2Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D2Homo sapiens (human)
synaptic vesicle recyclingPhospholipase D2Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisPhospholipase D2Homo sapiens (human)
phospholipid catabolic processPhospholipase D2Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen-related receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen-related receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayEstrogen-related receptor gammaHomo sapiens (human)
positive regulation of cold-induced thermogenesisEstrogen-related receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen-related receptor gammaHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen-related receptor gammaHomo sapiens (human)
phosphatidic acid biosynthetic processPhospholipase D1Homo sapiens (human)
chemotaxisPhospholipase D1Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D1Homo sapiens (human)
Ras protein signal transductionPhospholipase D1Homo sapiens (human)
cellular response to nutrientPhospholipase D1Homo sapiens (human)
regulation of microvillus assemblyPhospholipase D1Homo sapiens (human)
positive regulation of translationPhospholipase D1Homo sapiens (human)
regulation of synaptic vesicle cyclePhospholipase D1Homo sapiens (human)
phospholipid catabolic processPhospholipase D1Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of protein ubiquitinationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of protein localizationLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to UVLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to gamma radiationLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair-dependent chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuroblast proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
protein demethylationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neuron projection developmentLysine-specific histone demethylase 1AHomo sapiens (human)
cerebral cortex developmentLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
neuron maturationLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cell sizeLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific histone demethylase 1AHomo sapiens (human)
guanine metabolic processLysine-specific histone demethylase 1AHomo sapiens (human)
muscle cell developmentLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific histone demethylase 1AHomo sapiens (human)
response to fungicideLysine-specific histone demethylase 1AHomo sapiens (human)
cellular response to cAMPLysine-specific histone demethylase 1AHomo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific histone demethylase 1AHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of neural precursor cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of stem cell proliferationLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin remodelingLysine-specific histone demethylase 1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
ovulation from ovarian follicleProgesterone receptorHomo sapiens (human)
glandular epithelial cell maturationProgesterone receptorHomo sapiens (human)
regulation of DNA-templated transcriptionProgesterone receptorHomo sapiens (human)
signal transductionProgesterone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayProgesterone receptorHomo sapiens (human)
cell-cell signalingProgesterone receptorHomo sapiens (human)
positive regulation of gene expressionProgesterone receptorHomo sapiens (human)
negative regulation of gene expressionProgesterone receptorHomo sapiens (human)
paracrine signalingProgesterone receptorHomo sapiens (human)
negative regulation of phosphorylationProgesterone receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
lung alveolus developmentProgesterone receptorHomo sapiens (human)
regulation of epithelial cell proliferationProgesterone receptorHomo sapiens (human)
progesterone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
maintenance of protein location in nucleusProgesterone receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisProgesterone receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIProgesterone receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayProgesterone receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (87)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
phospholipase D activityPhospholipase D2Homo sapiens (human)
protein bindingPhospholipase D2Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D2Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen-related receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen-related receptor gammaHomo sapiens (human)
nuclear steroid receptor activityEstrogen-related receptor gammaHomo sapiens (human)
steroid bindingEstrogen-related receptor gammaHomo sapiens (human)
protein bindingEstrogen-related receptor gammaHomo sapiens (human)
zinc ion bindingEstrogen-related receptor gammaHomo sapiens (human)
AF-2 domain bindingEstrogen-related receptor gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen-related receptor gammaHomo sapiens (human)
estrogen response element bindingEstrogen-related receptor gammaHomo sapiens (human)
nuclear receptor activityEstrogen-related receptor gammaHomo sapiens (human)
phospholipase D activityPhospholipase D1Homo sapiens (human)
protein bindingPhospholipase D1Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D1Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
telomeric DNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
p53 bindingLysine-specific histone demethylase 1AHomo sapiens (human)
chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
oxidoreductase activityLysine-specific histone demethylase 1AHomo sapiens (human)
enzyme bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific histone demethylase 1AHomo sapiens (human)
demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
identical protein bindingLysine-specific histone demethylase 1AHomo sapiens (human)
MRF bindingLysine-specific histone demethylase 1AHomo sapiens (human)
flavin adenine dinucleotide bindingLysine-specific histone demethylase 1AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
telomeric repeat-containing RNA bindingLysine-specific histone demethylase 1AHomo sapiens (human)
DNA-binding transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
FAD-dependent H3K4me/H3K4me3 demethylase activityLysine-specific histone demethylase 1AHomo sapiens (human)
promoter-specific chromatin bindingLysine-specific histone demethylase 1AHomo sapiens (human)
transcription factor bindingLysine-specific histone demethylase 1AHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
transcription coactivator bindingProgesterone receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProgesterone receptorHomo sapiens (human)
DNA bindingProgesterone receptorHomo sapiens (human)
nuclear steroid receptor activityProgesterone receptorHomo sapiens (human)
G protein-coupled receptor activityProgesterone receptorHomo sapiens (human)
steroid bindingProgesterone receptorHomo sapiens (human)
protein bindingProgesterone receptorHomo sapiens (human)
zinc ion bindingProgesterone receptorHomo sapiens (human)
enzyme bindingProgesterone receptorHomo sapiens (human)
identical protein bindingProgesterone receptorHomo sapiens (human)
ATPase bindingProgesterone receptorHomo sapiens (human)
estrogen response element bindingProgesterone receptorHomo sapiens (human)
nuclear receptor activityProgesterone receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (44)

Processvia Protein(s)Taxonomy
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
endoplasmic reticulum membranePhospholipase D2Homo sapiens (human)
plasma membranePhospholipase D2Homo sapiens (human)
presynapsePhospholipase D2Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D2Homo sapiens (human)
plasma membrane regionPhospholipase D2Homo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleoplasmEstrogen-related receptor gammaHomo sapiens (human)
chromatinEstrogen-related receptor gammaHomo sapiens (human)
nucleusEstrogen-related receptor gammaHomo sapiens (human)
cholinergic synapsePhospholipase D1Homo sapiens (human)
Golgi membranePhospholipase D1Homo sapiens (human)
lysosomal membranePhospholipase D1Homo sapiens (human)
endosomePhospholipase D1Homo sapiens (human)
endoplasmic reticulum membranePhospholipase D1Homo sapiens (human)
Golgi apparatusPhospholipase D1Homo sapiens (human)
plasma membranePhospholipase D1Homo sapiens (human)
membranePhospholipase D1Homo sapiens (human)
apical plasma membranePhospholipase D1Homo sapiens (human)
endocytic vesiclePhospholipase D1Homo sapiens (human)
late endosome membranePhospholipase D1Homo sapiens (human)
specific granule membranePhospholipase D1Homo sapiens (human)
perinuclear region of cytoplasmPhospholipase D1Homo sapiens (human)
tertiary granule membranePhospholipase D1Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D1Homo sapiens (human)
plasma membrane regionPhospholipase D1Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
chromatinLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
chromosome, telomeric regionLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusLysine-specific histone demethylase 1AHomo sapiens (human)
nucleoplasmLysine-specific histone demethylase 1AHomo sapiens (human)
transcription regulator complexLysine-specific histone demethylase 1AHomo sapiens (human)
protein-containing complexLysine-specific histone demethylase 1AHomo sapiens (human)
DNA repair complexLysine-specific histone demethylase 1AHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneProgesterone receptorHomo sapiens (human)
nucleoplasmProgesterone receptorHomo sapiens (human)
mitochondrial outer membraneProgesterone receptorHomo sapiens (human)
cytosolProgesterone receptorHomo sapiens (human)
chromatinProgesterone receptorHomo sapiens (human)
nucleusProgesterone receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (217)

Assay IDTitleYearJournalArticle
AID473402Estrogenic activity in human ERalpha expressing MCF7:WS8 cells assessed as stimulation of cell proliferation after 7 days2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID102448Inhibitory activity against proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]- estradiol (E2)1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID164970The percent stimulation or inhibition of protein kinase C III activity was determined for phosphatidylserine (PS) and diolein(PS+DO) in the presence of [Ca2+]1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID42278Inhibitory activity against proliferation of BT-20 cells in presence of TPE at 10e-5 M concentration.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID237576Octanol-water partition coefficient (logP) of the compound measured by RP-HPLC2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
AID1690970Antagonist activity at ERbeta (unknown origin) expressed in human U2OS cells assessed as inhibition of E2-induced transactivation measured after 21 hrs by dual luciferase reporter gene assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1690969Antagonist activity at ERalpha (unknown origin) expressed in human U2OS cells assessed as inhibition of E2-induced transactivation measured after 21 hrs by dual luciferase reporter gene assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1690957Displacement of fluorescent-labelled E2 from recombinant human GST-tagged ERbeta by LanthaScreen TR-FRET assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1690985Antiproliferative activity against human SK-BR-3 cells assessed as cell mass at 20 uM measured after 72 hrs by crystal violet staining based assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1690959Displacement of fluorescent-labelled E2 from recombinant human GST-tagged ERbeta by LanthaScreen TR-FRET assay relative to E22020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID473405Antiestrogenic activity in human MCF7 cells assessed as inhibition of estradiol-stimulated proliferation2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID103600Agonistic activity in MCF-7 cell proliferation.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID71134Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 5 hours at 25 degree Centigrade.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1690990Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell metabolic activity up to 20 uM measured after 72 hrs by modified MTT based EZ4U assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID102623Percent of inhibitory activity against proliferation of MCF-7 cells in presence of 10e-6 M concentration of [3H]estradiol (E2).1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID71132Relative binding affinity was measured on calf uterus estrogen receptor after 5 hr at 25C.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID1690973Selective estrogen receptor alpha modulator activity in human MCF7 cells assessed as residual ERalpha level at 1 uM measured after 24 hrs by Western blot analysis (Rvb = 100%)2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID103758Cytostatic activity against MCF-7 cell proliferation1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID38612Relative binding affinity for antiestrogen binding site (AEBS) of calf uterus 2 hr incubation at 0C1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1690980Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell mass measured after 72 hrs by crystal violet staining based assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID164971Percent stimulation or inhibition of protein kinase C III activity for phosphatidylserine (PS) in the presence of [Ca2+].1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID1690960Selectivity ratio of IC50 for displacement of fluorescent-labelled E2 from recombinant human GST-tagged ERalpha to IC50 for displacement of fluorescent-labelled E2 from recombinant human GST-tagged ERbeta2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1690982Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell mass at 10 uM measured after 72 hrs by crystal violet staining based assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID71116Inhibition of [3H]estradiol binding to calf uterine Estrogen receptor relative to tamoxifen1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
AID71114Inhibition of [3H]estradiol binding to Estrogen receptor of MCF-7 cell lysate relative to tamoxifen1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
AID1690984Antiproliferative activity against human MDA-MB-231 cells assessed as cell mass at 20 uM measured after 72 hrs by crystal violet staining based assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1432443Inverse agonist activity at GAL4-DNA binding domain-fused human ERRbeta ligand binding domain expressed in African green monkey CV1 cells assessed as decrease in receptor transcriptional activity after 45 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID1432452Displacement of [3H]-estradiol from rat uterine cytosolic estrogen receptor at 10'-10 to 10'-4 M by scintillation counting method relative to estradiol2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID38611Relative binding affinity for antiestrogen binding site (AEBS) of calf uterus cytosol1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1690987Antiproliferative activity against human MCF7 cells assessed as reduction in cell metabolic activity at 20 uM measured after 72 hrs by modified MTT based EZ4U assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID1432444Inverse agonist activity at GAL4-DNA binding domain-fused mouse ERRgamma ligand binding domain expressed in African green monkey CV1 cells assessed as decrease in receptor transcriptional activity after 45 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID234090Selectivity for relative binding affinity against estrogen receptor at 2 hrs and 5 hr in calf uterus cytosol1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1690979Antiproliferative activity against human MCF7 cells assessed as reduction in cell mass measured after 72 hrs by crystal violet staining based assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID102435Effective dose for [3H]- estradiol against proliferation of MCF-7 cells1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1690956Displacement of fluorescent-labelled E2 from recombinant human GST-tagged ERalpha by LanthaScreen TR-FRET assay2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID102602In vitro inhibition of MCF-7 cell proliferation compared to 0.1 nM [3H]-estradiol.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID473404Antiestrogenic activity in human MCF7 cells assessed as inhibition of estradiol-stimulated prolactin gene expression2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1432448Inverse agonist activity at GAL4-DNA binding domain-fused human ERRalpha ligand binding domain expressed in African green monkey CV1 cells assessed as decrease in receptor transcriptional activity after 45 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
AID1690983Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell mass at 10 uM measured after 72 hrs by crystal violet staining based assay relative to control2020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID164972Percent stimulation or inhibition of protein kinase C III activity for protamine sulfate in the presence of EGTA.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicated in estrogen receptor binding, protein kinase C activity, and MCF7 cell proliferation.
AID1690958Displacement of fluorescent-labelled E2 from recombinant human GST-tagged ERalpha by LanthaScreen TR-FRET assay relative to E22020European journal of medicinal chemistry, Apr-15, Volume: 192Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.
AID71133Relative binding affinity against estrogen receptor in calf uterus cytosol using [3H]E2 as radioligand, incubated at 2 hours at 0 degree Centigrade.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID42280Percent of inhibitory activity against proliferation of BT-20 cells in presence of TPE at 10e-5 M concentration.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID102624Percent of inhibitory activity versus 0.1 nm [3H]estradiol against proliferation of MCF-7 cells.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID102768Percent of effective dose for [3H]estradiol against proliferation of MCF-7 cells.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth.
AID1263143Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1615811Antiproliferative activity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
α-Pyrone and Sterol Constituents of
AID1901490Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10% CD-FBS and 17-beta-estradiol by alamar blue assay2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer.
AID1829681Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 120 hrs by crystal violet staining based assay
AID1385434Inhibition of NFkappaB in mouse RAW 264.7 cells assessed as reduction in LPS induced NO production at 10 uM after 24 hrs by Griess assay relative to control2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
AID1768144Intrinsic clearance in rat hepatocytes measured up to 60 mins by LC/MS/MS analysis
AID1768207Invivo agonist activity at estrogen receptor in CRL:CD(SD) rat assessed as increase in uterine wet weight to body weight ratio at 60 mg/kg, po administered for 4 days and measured at 4 hr post last dose on day 4 relative to control
AID1163075Safety index, ratio of IC50 for human MCF10A cells to EC50 for human ER-negative MCF7 cells2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1830575Displacement of fluorescent labeled-ligand from ERalpha (unknown origin) by competitive binding assay2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
AID1263145Inhibition of human recombinant HDAC6 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1163072Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1768145Clearance in Sprague-Dawley rat at 1 mg/kg, iv or po measured after 0.033 to 24 hrs by LC/MS/MS analysis
AID1163076Safety index, ratio of IC50 for human MCF10A cells to EC50 for human ER-positive MDA-MB-231 cells2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1163074Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1594508Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1551092Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay2019European journal of medicinal chemistry, Jun-15, Volume: 172Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
AID1829665Displacement of fluorescent-labeled E2 from LBD of ERalpha (unknown origin) assessed as relative binding affinity by TR-FRET assay relative to control
AID1829680Antiproliferative activity against human MCF-7/TAMR-1 cells assessed as reduction in cell viability measured after 120 hrs by crystal violet staining based assayy
AID1559008Cytotoxicity against human T47D monolayer cells harboring Y537S mutant assessed as reduction in tumor cell viability at 10 nM incubated for 10 days by celltiter-glo 3D cell viability assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID1163062Antiproliferative activity against human prostate, androgen receptor positive DU145 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1829690Cytostatic effect on human MDA-MB-231 cells at 10 uM assessed as ratio of T/C measured up to 144 hrs relative to control
AID1829663Displacement of fluorescent-labeled E2 from LBD of ERalpha (unknown origin) by TR-FRET assay
AID1763815Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1469729Induction of selective estrogen receptor alpha degradation in human MCF7 cells harboring TK-ERE-Luc assessed as reduction in estradiol-induced GREB1 mRNA expression after 24 hrs by TaqMan assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
AID1536996Induction of VP16-labeled ERalpha (unknown origin) conformational changes ezpressed in HEK293T cells after 24 hrs by luciferase reporter gene assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.
AID1906899Anti-hyperplasia activity in human MCF7 cells xenografted in Sprague-Dawley rat assessed as appearance of tall columnar phenotype in epithelial cells at 60 mg/kg, po once daily for 3 days by hematoxylin and eosin staining based assay2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Discovery of Thieno[2,3-
AID1763816Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1469717Induction of selective estrogen receptor alpha degradation in human MCF7 cells harboring TK-ERE-Luc assessed as reduction in estradiol-induced transcriptional activity after 24 hrs by luciferase reporter gene assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
AID1911242Selectivity index, ratio of IC50 for human MCF-10A cells to IC50 for human MCF-7 cells2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
AID1911238Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
AID1364838Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
AID1768210Invivo agonist activity at estrogen receptor in CRL:CD(SD) rat assessed as appearance of low cuboidal phenotype of epithelium at 0.1 mg/kg, po administered for 4 days and measured at 4 hr post last dose on day 4 by hematoxylin and eosin staining based ass
AID1768203Antiproliferative activity against human T47D incubated for 7 to 10 days by celltiter-glo luminescent cell viability assay
AID1768143Intrinsic clearance in human hepatocytes measured up to 60 mins by LC/MS/MS analysis
AID1263144Inhibition of human recombinant HDAC3 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1337046Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
AID1594509Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1768140Induction of estrogen receptor degradation in human MCF7 cells at 0.0002 to 100 nM incubated for 4 hrs by Alexafluor-488 conjugate anti-mouse IgG staining based fluorescence method relative to control
AID1163061Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1506598Displacement of Fluormone ES2 Green from full-length untagged human ERalpha expressed in insect cells after 2 hrs by fluorescence polarization assay2017MedChemComm, Jan-01, Volume: 8, Issue:1
Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton.
AID1768141Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
AID1901456Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10% CD-FBS by alamar blue assay2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer.
AID1911239Antiproliferative activity against tamoxifen-resistant human LCC2 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
AID1163060Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1710767Antagonist activity at estrogen receptor in human MCF7 cells assessed as E2-induced progesterone receptor mRNA expression level at 1 uM incubated for 24 hrs by real time PCR analysis (Rvb = 100%)2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
AID1829679Antiproliferative activity against human ER-positive MCF7 cells assessed as reduction in cell viability measured after 120 hrs by crystal violet staining based assay
AID1911240Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
AID1911241Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured after 72 hrs by Cell Counting Kit-8 assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
AID1768142Kinetic solubility of compound at pH 7.4
AID1469728Antiproliferative activity against human MCF7 cells after 6 days in presence of estradiol by CellTiter-Glo assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
AID1263142Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1337045Displacement of fluormone-labeled ES2 from recombinant full length human ERalpha ligand binding domain expressed in insect cells after 2 hrs by TR-FRET assay
AID1768149Distribution coefficient, logD of the compound at pH 7.4
AID1594504Induction of ERalpha degradation in human MCF7 cells at 1 uM by Western blot analysis2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1768138Antagonist activity at estrogen receptor in human T47D cells incubated for 18 hrs by ultra high sensitivity luminescence reporter gene assay
AID1364836Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
AID1163073Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1385436Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
AID1163064Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1559007Cytotoxicity against human T47D monolayer cells assessed as reduction in tumor cell viability at 10 nM incubated for 10 days by celltiter-glo 3D cell viability assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID1763818Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for human MCF7 cells2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1469718Induction of selective estrogen receptor alpha degradation in human MCF7 cells assessed as ERalpha remaining at 10 uM after 18 to 24 hrs by in-cell Western analysis relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
AID1163063Antiproliferative activity against human ER-positive Ishikawa cells after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
AID1768139Induction of estrogen receptor degradation in human MCF7 cells incubated for 4 hrs by Alexafluor -488 conjugate anti-mouse IgG staining based fluorescence method
AID1829692Cytocidal effect on human MCF7/TAMR-1 cells at 10 uM assessed as ratio of T/C measured up to 144 hrs relative to control
AID1768204Antiproliferative activity against human CAMA-1 incubated for 7 to 10 days by celltiter-glo luminescent cell viability assay
AID1829664Displacement of fluorescent-labeled E2 from LBD of ERbeta (unknown origin) by TR-FRET assay
AID1829666Displacement of fluorescent-labeled E2 from LBD of ERbeta (unknown origin) assessed as relative binding affinity by TR-FRET assay relative to control
AID1911294Induction of mitochondrial membrane potential loss in tamoxifen-resistant human LCC2 cells at 15 uM incubated for 48 hrs by JC-1 staining based flow cytometry2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
AID1307756Inhibition of human placental microsomal aromatase using testosterone as substrate assessed as formation of estradiol after 10 mins2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.
AID1829675Antagonist activity at ERalpha (unknown origin) expressed in human U2OS cells assessed as inhibition of E2-induced transactivation by dual luciferase reporter gene assay
AID1594506Binding affinity to GST-tagged human ER alpha ligand-binding domain by TR-FRET assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1846781Inhibition of ERalpha (unknown origin) in MCF7 cells measured after 24 to 48 hrs by FRET assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
AID1829676Antagonist activity at ERbeta (unknown origin) expressed in human U2OS cells assessed as inhibition of E2-induced transactivation by dual luciferase reporter gene assay
AID1829678Induction of ERalpha degradation in human MCF7 cells assessed as efficacy at 1 uM incubated for 72 hrs by Western immuno assay relative to control
AID1364837Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
AID1559009Cytotoxicity against human T47D monolayer cells harboring D538G mutant assessed as reduction in tumor cell viability at 10 nM incubated for 10 days by celltiter-glo 3D cell viability assay2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
AID1594511Agonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ER-alpha-mediated transcriptional activity at 10 uM by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1829691Cytocidal effect on human MCF7 cells at 10 uM assessed as ratio of T/C measured up to 144 hrs relative to control
AID1829677Induction of ERalpha degradation in human MCF7 cells assessed as ERalpha remaining level at 1 uM incubated for 72 hrs by Western immuno assay relative to control
AID1768205Antiproliferative activity against human HCC1500 incubated for 7 to 10 days by celltiter-glo luminescent cell viability assay
AID1385433Inhibition of NFkappaB in mouse RAW 264.7 cells assessed as reduction in LPS induced NO production after 24 hrs by Griess assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
AID1263146Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1594510Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay relative to untreated control2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1906874In vivo agonist activity at ERalpha in immature Sprague-Dawley rat assessed as fold increase in uterine wet weight to body weight ratio at 60 mg/kg, po once daily for 3 days2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Discovery of Thieno[2,3-
AID1768206Invivo agonist activity at estrogen receptor in CRL:CD(SD) rat assessed as increase in uterine wet weight to body weight ratio at 0.1 mg/kg, po administered for 4 days and measured at 4 hr post last dose on day 4 relative to control
AID1337047Cytotoxicity against tamoxifen-resistant human MCF7 cells assessed as reduction in cell viability after 5 days by Coulter counting method
AID1763817Antiproliferative activity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
AID1768202Antiproliferative activity against human MCF7 incubated for 7 to 10 days by celltiter-glo luminescent cell viability assay
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1797989ER-alpha Radioligand Binding Assay and ERE-Luciferase Reporter Assay. from Article 10.1021/jm030086h: \\Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.\\2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
AID1798194Radioligand Displacement Assay from Article 10.1016/j.bmcl.2005.11.030: \\Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.\\2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID1801138In vivo Deuterated 1-Butanol PLD Assay from Article 10.1021/cb500828m: \\Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.\\2015ACS chemical biology, Feb-20, Volume: 10, Issue:2
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
AID1801141Exogenous PldA Assay from Article 10.1021/cb500828m: \\Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.\\2015ACS chemical biology, Feb-20, Volume: 10, Issue:2
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes.
AID1798195ERRgamma FRET Assay from Article 10.1021/jm050161j: \\Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.\\2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.
AID1799022Radioligand Displacement Assay from Article 10.1016/j.bbrc.2008.06.050: \\ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner.\\2008Biochemical and biophysical research communications, Aug-29, Volume: 373, Issue:3
ERRgamma tethers strongly bisphenol A and 4-alpha-cumylphenol in an induced-fit manner.
AID1865897Antagonist activity at ERalpha in human MCF7 cells assessed as inhibition of p-ERK1/2 activation at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID1629293Antiproliferative activity against human T47D cells after 5 days by coulter counter analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
AID1865896Antagonist activity at ERalpha in human MCF7 cells assessed as inhibition of p-Raf-1 activation at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID1752639Induction of cell proliferation in human ishikawa cells at 156 to 5000 nM measured after 2 days2021Bioorganic & medicinal chemistry, 10-01, Volume: 47Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.
AID1865917Lipophilicity, logD of the compound by shake-flask method
AID1865894Antagonist activity at progesterone receptor in human MCF7 cells
AID1865888Relative binding affinity to ERbeta (unknown origin)
AID1865914Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G2/M phase at 0.1 nM after 24 hrs
AID1865919Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor latency time at 50 mg/kg, po
AID1865893Antagonist activity at ERalpha in human MCF7 cells assessed as downregulation of ERalpha
AID1865925Plasma protein binding in rat at 50 mg/kg, po
AID1865905Downregulation of hERE gene transcription expression in human MCF7 cells at 0.1 to 1 nM measured by luciferase reporter gene assay
AID1865912Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at S phase at 1 nM after 24 hrs
AID1865887Relative binding affinity to ERalpha (unknown origin)
AID1865932Toxicity in female Wistar rat xenografted with methyl nitroso urea (MNU)-preinduced breast cancer assessed as severe necrosis at 5 mg/kg, po
AID1865885Antagonist activity at ERalpha (unknown origin)
AID1865908Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G0/G1 phase at 0.1 nM after 24 hrs
AID1865926Oral bioavailability in rat at 5 mg/kg
AID170810Anti-uterotrophic effect in rats at 50 ug/animal/day in the presence of 0.5 ug estradiol benzoate1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID1865923Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor volume at 50 mg/kg, po
AID1652275Growth inhibition of fulvestrant-resistant human MCF7:CFR 3D spheroid cells at 100 nM supplemented with fresh medium containing compound every 2 to 3 days for 9 days by celltitre-glo assay relative to control2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
AID1865918Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor latency time at 5 mg/kg, po
AID69517In vitro relative binding affinity for rat uterine estrogen receptor compared to [3H]estradiol1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Hydroxy derivatives of tamoxifen.
AID1865890Antiproliferative activity against human MDA-MB-231 cells
AID1865904Downregulation of hERE gene transcription expression in human MCF7 cells at 0.1 to 1 nM measured by luciferase reporter gene assay
AID1737495Inhibition of LSD1 (unknown origin) incubated for 90 mins by fluorescence based assay2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID1865927Oral bioavailability in rat at 50 mg/kg
AID1865886Antagonist activity at ERbeta (unknown origin)
AID1629295Antiproliferative activity against human tamoxifen-resistant T47D cells over-expressing PKC-alpha after 5 days by coulter counter analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
AID1865921Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor burden level at 50 mg/kg, po
AID1865889Antiproliferative activity against human MCF7 cells
AID1865915Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G2/M phase at 1 nM after 24 hrs
AID1737496Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay2020European journal of medicinal chemistry, Jun-01, Volume: 195Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
AID1865901Antagonist activity at ERalpha in human MCF7 cells assessed as effect on total levels of ERK1/2 at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID1865933Toxicity in female Wistar rat xenografted with methyl nitroso urea (MNU)-preinduced breast cancer assessed as severe necrosis at 50 mg/kg, po
AID1629294Antiproliferative activity against human tamoxifen-resistant MCF7 cells after 5 days by coulter counter analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
AID1865924Plasma protein binding in rat at 5 mg/kg, po
AID1779065Induction of ERalpha activity in human ishikawa cells assessed as induction of cell proliferation at 156 to 5000 nM measured after 3 days2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID1865892Antiproliferative activity against human MRC5 cells
AID1865911Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at S phase at 0.1 nM after 24 hrs
AID1629292Antiproliferative activity against human MCF7 cells after 5 days by coulter counter analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).
AID1865920Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor burden level at 5 mg/kg, po
AID191709Uterotrophic effect in rats at 50 ug/animal/day hydroxytamoxifen1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID69386Percent inhibition of [3H]estradiol binding to cytoplasmic estrogen receptor of rat uterus1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Estrogenic and antiestrogenic activity of monophenolic analogues of tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethylamine.
AID1865895Antiproliferative activity against human Ishikawa cells
AID1865922Antitumor activity against methyl nitroso urea (MNU)-preinduced human breast cancer in female Wistar rat assessed as tumor volume at 5 mg/kg, po
AID1865891Selectivity index, ratio IC50 for antiproliferative activity against human MDA-MB-231 cells over IC50 for antiproliferative activity against human MCF7 cells
AID1865900Antagonist activity at ERalpha in human MCF7 cells assessed as effect on total levels of Raf-1 at 0.1 to 1 nM measured after 24 hrs by Western blot analysis
AID1865909Induction of cell cycle arrest in human MCF7 cells assessed as cell accumulation at G0/G1 phase at 1 nM after 24 hrs
AID1346836Human Estrogen-related receptor-gamma (3B. Estrogen-related receptors)2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID1346880Human Estrogen receptor-beta (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)1997Endocrinology, Mar, Volume: 138, Issue:3
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.
AID1346845Human Estrogen receptor-alpha (3A. Estrogen receptors)2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.
AID1346836Human Estrogen-related receptor-gamma (3B. Estrogen-related receptors)2001Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 98, Issue:15
4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,230)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990159 (12.93)18.7374
1990's268 (21.79)18.2507
2000's424 (34.47)29.6817
2010's326 (26.50)24.3611
2020's53 (4.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.39 (24.57)
Research Supply Index7.14 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials10 (0.80%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews19 (1.51%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.16%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational2 (0.16%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other1,222 (97.37%)84.16%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ [NCT04570956]Phase 2/Phase 3104 participants (Anticipated)Interventional2021-07-26Recruiting
A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D [NCT03199963]Phase 3223 participants (Actual)Interventional2017-08-21Terminated(stopped due to Administrative - change in development strategy)
Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast [NCT00952731]Phase 227 participants (Actual)Interventional2009-12-31Completed
A Phase II, Randomized, Double-Blind, Two-Dose, Placebo-Controlled Multicentre Study of 4-Hydroxy Tamoxifen Gel for Cyclical Mastalgia in Otherwise Healthy Pre-Menopausal Women With Regular Menstrual Cycles. [NCT00272714]Phase 2146 participants (Actual)Interventional2003-03-31Completed
A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast [NCT03063619]Phase 2194 participants (Actual)Interventional2017-05-01Active, not recruiting
A Prospective, Randomized, Placebo-Controlled Trial of the Effects of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women [NCT00084344]0 participants Interventional2003-04-30Completed
Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast [NCT02993159]Phase 2100 participants (Anticipated)Interventional2017-05-31Recruiting
A Phase II Study of the Determinants of Transdermal Drug Delivery to the Normal and the Radiated Breast [NCT04009044]Phase 2156 participants (Anticipated)Interventional2020-02-17Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00952731 (6) [back to overview]Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment
NCT00952731 (6) [back to overview]Difference in Factor IX Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery
NCT00952731 (6) [back to overview]Difference in Factor VIII Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery
NCT00952731 (6) [back to overview]Difference in Mean Score for Vasomotor Symptoms Including Hot Flashes From Baseline to Time of Surgery
NCT00952731 (6) [back to overview]Difference in Protein S Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery
NCT00952731 (6) [back to overview]Difference in vWF Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery
NCT03199963 (6) [back to overview]Change in Serum Concentration of Select Bone Biomarkers: Bone Specific Alkaline Phosphatase (BSAP) (U/L)
NCT03199963 (6) [back to overview]Change in Serum Concentration of Select Bone Biomarkers:Type I Collagen C-Telopeptides (CTx) (pg/mL)
NCT03199963 (6) [back to overview]Change in Serum Concentration of Sex Hormone Binding Globulin (SHBG) From Baseline to Week 52/End of Study (EOS)
NCT03199963 (6) [back to overview]Change in Serum Concentration of: Cholesterol, Triglycerides, High-density Lipoprotein (HDL), and Low-density Lipoprotein (LDL).
NCT03199963 (6) [back to overview]Number and Severity of Adverse Events (AEs)
NCT03199963 (6) [back to overview]Number of Participants With Measurable Plasma Concentrations of the E and Z Isomers of 4-OHT by Visit

Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment

Ki-67 was measured in matched core and excision tissue samples containing DCIS (Ductal Carcinoma In-Situ) lesions, the core sample was at baseline while the excision sample was at surgery (after approximately 4-10 weeks of treatment). (NCT00952731)
Timeframe: Baseline and after 4-10 weeks of treatment

Interventionpercentage of 300 DCIS cells (Mean)
Treatment Gel + Oral Placebo-3.4
Placebo Gel + Oral Treatment-5.1

[back to top]

Difference in Factor IX Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery

The difference between Factor IX coagulation protein in blood samples collected at baseline and before surgery was measured with VisuLize antigen ELISA Kits. (NCT00952731)
Timeframe: Baseline and immediately before surgery (after approximately 4-10 weeks)

Interventionpercentage of Factor IX protein in blood (Mean)
Treatment Gel + Oral Placebo-5.6
Placebo Gel + Oral Treatment0.4

[back to top]

Difference in Factor VIII Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery

The difference between Factor VIII coagulation protein in blood samples collected at baseline and before surgery was measured with VisuLize antigen ELISA Kits. (NCT00952731)
Timeframe: Baseline and immediately before surgery (after approximately 4-10 weeks)

Interventionpercentage Factor VIII protein in blood (Mean)
Treatment Gel + Oral Placebo8.7
Placebo Gel + Oral Treatment11.6

[back to top]

Difference in Mean Score for Vasomotor Symptoms Including Hot Flashes From Baseline to Time of Surgery

Hot flashes were assessed by the Breast Cancer Prevention Trial Eight Symptom Scale (BESS) questionnaire. This questionnaire measures the incidence of a number of symptoms by asking participants how frequently they experienced them on a scale of 0-4 (0 being Not at All and 4 being Extremely often). BESS questionnaire was administered at baseline and time of surgery. The incidence of vasomotor symptoms (including hot flashes, night sweats, and cold sweats) was measured at baseline (Day 0) and end of treatment prior to surgery (at least 4 weeks later or up to 10 weeks, depending on scheduled surgery date), and changes in the mean score for hot flashes were observed. (NCT00952731)
Timeframe: Baseline and after 4-10 weeks of treatment

Interventionunits on a scale (Mean)
Treatment Gel + Oral Placebo0.33
Placebo Gel + Oral Treatment0.55

[back to top]

Difference in Protein S Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery

The difference between protein S coagulation protein in blood samples collected at baseline and before surgery was measured using an ELISA Kit. (NCT00952731)
Timeframe: Baseline and immediately before surgery (after approximately 4-10 weeks)

Interventionpercentage of protein S in blood (Mean)
Treatment Gel + Oral Placebo-1.6
Placebo Gel + Oral Treatment-2.7

[back to top]

Difference in vWF Coagulation Protein in Blood Collected at Baseline and Just Prior to Surgery

The difference between vWF coagulation protein in blood samples collected at baseline and before surgery were measured using the immune-turbidimetric assay. (NCT00952731)
Timeframe: Baseline to immediately before surgery (after approximately 4-10 weeks)

Interventionpercentage of vWF protein in blood (Mean)
Treatment Gel + Oral Placebo-2.6
Placebo Gel + Oral Treatment51.2

[back to top]

Change in Serum Concentration of Select Bone Biomarkers: Bone Specific Alkaline Phosphatase (BSAP) (U/L)

Bone biomarker levels (BSAP) at baseline will be compared to levels measured at Week 52. (NCT03199963)
Timeframe: Blinded Phase: Baseline; Week 52/EOS

InterventionBSAP in U/L (Mean)
BHR-700 (0.2% 4-OHT Gel)1.0
Matching Placebo Gel0.7

[back to top]

Change in Serum Concentration of Select Bone Biomarkers:Type I Collagen C-Telopeptides (CTx) (pg/mL)

Bone biomarker levels (CTx) at baseline will be compared to levels measured at Week 52. (NCT03199963)
Timeframe: Blinded Phase: Baseline; Week 52/EOS

Interventionpg/mL (Mean)
BHR-700 (0.2% 4-OHT Gel)-19.6
Matching Placebo Gel3.7

[back to top]

Change in Serum Concentration of Sex Hormone Binding Globulin (SHBG) From Baseline to Week 52/End of Study (EOS)

SHBG levels at baseline will be compared to levels at Week 52/EOS (NCT03199963)
Timeframe: Blinded Phase: Baseline; Week 52/EOS

Interventionmg/L (Mean)
BHR-700 (0.2% 4-OHT Gel)0.1
Matching Placebo Gel0.3

[back to top]

Change in Serum Concentration of: Cholesterol, Triglycerides, High-density Lipoprotein (HDL), and Low-density Lipoprotein (LDL).

Lipid levels at baseline will be compared to levels measured at time-points in the study (NCT03199963)
Timeframe: Blinded Phase: Baseline; Weeks 26, 52/EOS.

,
Interventionmmol/L (Mean)
Cholesterol (mmol/L) - Change from Baseline to Week 26Cholesterol (mmol/L) - Change from Baseline to Week 52/EOSTriglycerides (mmol/L) - Change from Baseline to Week 26Triglycerides (mmol/L) - Change from Baseline to Week 52/EOSHDL Cholesterol (mmol/L) - Change from Baseline to Week 26HDL Cholesterol (mmol/L) - Change from Baseline to Week 52/EOSLDL Cholesterol (mmol/L) - Change from Baseline to Week 26LDL Cholesterol (mmol/L) - Change from Baseline to Week 52/EOS
BHR-700 (0.2% 4-OHT Gel)-0.10.1-0.2-0.1-0.00.00.00.1
Matching Placebo Gel-0.20.0-0.20.00.00.0-0.1-0.0

[back to top]

Number and Severity of Adverse Events (AEs)

AEs monitored and reported throughout study (NCT03199963)
Timeframe: Blinded Phase: Baseline; Weeks 13, 26, 39, 52/EOS and Open Label Phase

,,,
InterventionParticipants (Count of Participants)
Subjects with at least one mild AESubjects with at least one moderate AESubjects with at least one severe AE
BHR-700 (0.2% 4-OHT Gel) in Blinded Phase56498
Matching Placebo Gel in Blinded Phase31294
Open Label BHR-700 (0.2% 4-OHT Gel) Following BHR-700 in Blinded Phase221
Open Label BHR-700 (0.2% 4-OHT Gel) Following Placebo in Blinded Phase110

[back to top]

Number of Participants With Measurable Plasma Concentrations of the E and Z Isomers of 4-OHT by Visit

Blood samples will be taken to measure plasma concentrations of 4-OHT at time-points in the study (NCT03199963)
Timeframe: Blinded Phase: Weeks 13, 26, 52/EOS

InterventionParticipants (Count of Participants)
Week 13 E-4-OHT72545323Week 26 E-4-OHT72545323Week 52/EOS E-4-OHT72545323Week 13 Z-4-OHT72545323Week 26 Z-4-OHT72545323Week 52/EOS Z-4-OHT72545323
Participants with concentration below lower limit Participants with measurable concentration
BHR-700 (0.2% 4-OHT Gel)12
BHR-700 (0.2% 4-OHT Gel)128
BHR-700 (0.2% 4-OHT Gel)7
BHR-700 (0.2% 4-OHT Gel)88
BHR-700 (0.2% 4-OHT Gel)0
BHR-700 (0.2% 4-OHT Gel)179
BHR-700 (0.2% 4-OHT Gel)75
BHR-700 (0.2% 4-OHT Gel)65
BHR-700 (0.2% 4-OHT Gel)48
BHR-700 (0.2% 4-OHT Gel)47
BHR-700 (0.2% 4-OHT Gel)16
BHR-700 (0.2% 4-OHT Gel)163

[back to top]